Project Grant F31DA063338
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $139,927 to the University of Washington to study the impact of chronic, voluntary fentanyl intake on gene expression and neural activity patterns in the brain. The key objectives are to: 1) Conduct single-cell RNA sequencing analysis of the nucleus accumbens to assess changes in gene expression following chronic fentanyl self-administration and...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a 5-year Project Grant of $184,706 to the University of North Carolina at Chapel Hill (UNC-CH) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant will fund research to investigate the impact of fentanyl consumption on noradrenergic plasticity in the basolateral amygdala, a key component of the stress response. Specifically, the project will develop a mouse model of...
- This federal Project Grant award of $457,701 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to understand the pharmacodynamics of combined methamphetamine and fentanyl use. The primary objectives are to: 1) elucidate the mechanisms underlying polysubstance use disorders involving stimulants and opioids, and 2) investigate the role of the hypocretin/orexin neuropeptide system as a potential target for...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $193,250 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Trustees of Tufts College, doing business as Tufts University School of Medicine in Boston, Massachusetts. The grant, awarded on September 15, 2025, aims to determine whether fentanyl overdose induces an anhedonic phenotype, which in turn increases the risk of relapse in individuals with opioid use...
- This Project Grant award of $587,188.00 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a multi-omics research study on the impact of fentanyl use on cells susceptible to HIV infection. The research aims to evaluate the effects of fentanyl on the single-cell transcriptome and microRNA profiles in various peripheral blood mononuclear cell types, including CD4+ and CD8+ T lymphocytes, monocytes, B lymphocytes, dendritic...
- This federal Project Grant award from the National Institute on Drug Abuse (NIDA), part of the U.S. Department of Health and Human Services, is funded through the Drug Use and Addiction Research Programs (CFDA 93.279). The $454,251 award will support the development of a new approach for long-term monitoring of opioid-induced changes in neural population activity and opioid receptor gene expression in mice exposed to fentanyl. Specifically, the project aims to create "erasable"...
- This federal Project Grant award for $340,000 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund research to better understand the role of the locus coeruleus-noradrenergic (LC-NE) system in fentanyl withdrawal-induced negative affect behaviors. The research aims to determine whether a newly identified midbrain glutamatergic input to the LC contributes to the negative affective behaviors associated with opioid withdrawal....
- This $1,039,420 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to study the neuronal ensembles and circuits involved in the facilitation and disinhibition of opioid and alcohol seeking behaviors. The 5-year project, which begins on June 1, 2025 and runs through February 28, 2030, will employ innovative techniques such as single-nucleus RNA sequencing, spatial sequencing, and in vivo...
- This $265,302 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to investigate the neural mechanisms underlying opioid use disorder (OUD) and relapse risk during abstinence. The funded project will map the functional and anatomical pathways between the anterior and posterior paraventricular nucleus of the thalamus (PVT) and the nucleus accumbens (NAc), which have been implicated in the...
- This $403,542 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to profile projection-specific proteome associated with the incubation of oxycodone craving. The project will focus on the orbitofrontal cortex (OFC) to dorsal striatum (DS) projections, analyzing proteome changes in OFC neuronal somas (Aim 1) and OFC-DS projection-specific synaptoneurosomes in the DS (Aim 2) during the incubation of oxycodone...
EVALUATING THE MULTISCALE EFFECTS OF FENTANYL-INDUCED DEPENDENCE AND ABSTINENCE WITHIN THE MOUSE BASOLATERAL AMYGDALA - PROJECT SUMMARY / ABSTRACT THE UNITED STATES IS INTENSELY AFFECTED BY AN ONGOING OPIOID CRISIS. THIS CRISIS HAS GARNERED NATIONAL ATTENTION AND CAUSED THE MOBILIZATION OF NATIONAL RESOURCES TO ABATE THE ONGOING CRISIS. IN THE PREVIOUS FOUR YEARS, THE U.S. HAS SUFFERED IN EXCESS OF 300,000 DEATHS DUE TO OVERDOSE (OD). OVER 200,000 OF THESE DEATHS CAN BE DIRECTLY ATTRIBUTED TO FENTANYL ABUSE. DUE TO THE INCREDIBLE POTENCY, AVAILABILITY AND ADDICTIVE PROPERTIES, FENTANYL RELATED DEATHS SHOW NO SIGNS OF DECELERATING. DUE TO THE PERSISTENT DYSPHORIA AND ANHEDONIA IN ABSTINENCE, FENTANYL USERS ARE AT AN IMMENSE 4-8 TIMES INCREASED RISK OF OVERDOSE AFTER ABSTINENCE. THIS UNDERSCORES THE IMPORTANCE AND URGENCY BY WHICH NEW RESEARCH NEEDS TO INTERROGATE THE SUBSTRATES PREDISPOSING RELAPSE. NOVEL INVESTIGATIVE RESEARCH MUST BE EMPLOYED TO BETTER UNDERSTAND THE MECHANISMS BY WHICH FENTANYL INDUCES SUCH DEPENDENCE AND WHAT PERSISTENT CHANGES MAY CONTRIBUTE TO RELAPSE. THE MULTISCALE APPROACH IN THIS PROPOSAL AIMS TO COMPREHENSIVELY EVALUATE THE MOLECULAR, PROJECTION, AND BEHAVIORAL DYNAMICS DISRUPTED AS A RESULT OF FENTANYL DEPENDENCE AND INTERROGATE THESE DYNAMICS INTO ABSTINENCE. THIS APPROACH WILL INCORPORATE VIRALLY-MEDIATED STRATEGIES, NUCLEAR LABELING, AND SUBSEQUENT SINGLE- NUCLEUS RNA SEQUENCING TO EVALUATE HOW FENTANYL DEPENDENCE AND ABSTINENCE MAY DIFFERENTIALLY AFFECT PROJECTIONS IN THE BASOLATERAL AMYGDALA (BLA). THIS APPROACH ALLOWS FOR AN UNPRECEDENTED OBSERVATION INTO THE MOLECULAR MECHANISMS BY WHICH FENTANYL MAY DIFFERENTIALLY AFFECT REWARD-SEEKING PROJECTIONS VERSUS AVERSION- INDUCING PROJECTIONS WITH SINGLE-CELL RESOLUTION. NEXT, THIS PROPOSAL WILL ADDRESS HOW FENTANYL DEPENDENCE AND ABSTINENCE AFFECTS REWARDING AND PUNISHING EXPERIENCES BY COMBINING IN VIVO IMAGING WITH VARIOUS BEHAVIORS. THIS COMBINATION ENABLES A REAL-TIME VIEW OF THE BLA AS IT DIFFERENTIALLY MODULATES INDEPENDENT PROJECTIONS DURING VALENCED BEHAVIORS, AND IMPORTANTLY, ENABLES US TO OBSERVE HOW FENTANYL DEPENDENCE MAY DYSREGULATE THIS MODULATION EVEN AFTER ABSTINENCE. THIS WILL PROVIDE MOLECULAR RESOLUTION INTO HOW FENTANYL DIFFERENTIALLY AFFECTS SPECIFIC BLA PROJECTIONS ENCODING REWARD-SEEKING AND AVOIDANCE BEHAVIORS; THEN AIMS TO CAPTURE THE DYNAMICS OF THESE SPECIFIC PROJECTIONS IN VIVO WHILE ANIMALS PERFORM VALENCED BEHAVIORS. THIS MULTISCALE APPROACH FACILITATES A COMPREHENSIVE INVESTIGATION INTO THE MECHANISMS UNDERLYING HOW FENTANYL DEPENDENCE MAY DYSREGULATE POSITIVE OR NEGATIVE REINFORCEMENT, EVEN AFTER ABSTINENCE. THIS PROPOSAL IMPORTANTLY EVALUATES THE SIGNATURE FENTANYL DEPENDENCE IMPRINTS ON THE LIMBIC SYSTEM AND MAY PROVIDE NOVEL INSIGHTS INTO MECHANISMS PREDISPOSING RELAPSE. THE NATIONAL INSTITUTE OF DRUG ABUSE HAS SUPPORTED INNOVATIVE APPROACHES TO ELUCIDATE AND AMELIORATE DRUG DEPENDENCE AND RELAPSE FOR OVER 50 YEARS. WITH THEIR SUPPORT, THIS RESEARCH WILL PROVIDE A MULTIMODAL TRAINING PLAN AS WELL AS INSIGHTS INTO THE NEUROBIOLOGICAL UNDERPINNINGS OF FENTANYL ABUSE. THIS WILL PROVIDE COMPREHENSIVE TRAINING AND ALSO FACILITATE THE DEVELOPMENT OF NEW THERAPIES TO ABATE THE OPIOID CRISIS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $46.0k | 7/21/25 | ||
| Not listed | $46.0k | 7/21/25 | ||
| Not listed | $0 | 7/21/25 |